FI961632A0 - Menetelmä androgeenisen alopekian hoitamiseksi 5-alfa-reduktaasi-inhibiittoreilla - Google Patents

Menetelmä androgeenisen alopekian hoitamiseksi 5-alfa-reduktaasi-inhibiittoreilla

Info

Publication number
FI961632A0
FI961632A0 FI961632A FI961632A FI961632A0 FI 961632 A0 FI961632 A0 FI 961632A0 FI 961632 A FI961632 A FI 961632A FI 961632 A FI961632 A FI 961632A FI 961632 A0 FI961632 A0 FI 961632A0
Authority
FI
Finland
Prior art keywords
alpha
androgenic alopecia
reductase inhibitors
treating
treating androgenic
Prior art date
Application number
FI961632A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI961632A (fi
Inventor
Glenn J Gormley
Keith D Kaufman
Elizabeth Stoner
Joanne Waldstreicher
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26836279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI961632(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/214,905 external-priority patent/US5547957A/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of FI961632A publication Critical patent/FI961632A/fi
Publication of FI961632A0 publication Critical patent/FI961632A0/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A61Q7/02—Preparations for inhibiting or slowing hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI961632A 1993-10-15 1996-04-12 Menetelmä androgeenisen alopekian hoitamiseksi 5-alfa-reduktaasi-inhibiittoreilla FI961632A0 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13852093A 1993-10-15 1993-10-15
US08/214,905 US5547957A (en) 1993-10-15 1994-03-17 Method of treating androgenic alopecia with 5-α reductase inhibitors
PCT/US1994/011507 WO1995010284A1 (en) 1993-10-15 1994-10-11 Method of treating androgenic alopecia with 5-alpha reductase inhibitors

Publications (2)

Publication Number Publication Date
FI961632A FI961632A (fi) 1996-04-12
FI961632A0 true FI961632A0 (fi) 1996-04-12

Family

ID=26836279

Family Applications (1)

Application Number Title Priority Date Filing Date
FI961632A FI961632A0 (fi) 1993-10-15 1996-04-12 Menetelmä androgeenisen alopekian hoitamiseksi 5-alfa-reduktaasi-inhibiittoreilla

Country Status (28)

Country Link
US (3) US5824686A (pt)
EP (1) EP0724444B1 (pt)
JP (1) JP3058351B2 (pt)
CN (1) CN1096861C (pt)
AT (1) ATE156358T1 (pt)
BG (1) BG62756B1 (pt)
BR (1) BR9407824A (pt)
CA (1) CA2173457C (pt)
CY (1) CY2071B1 (pt)
CZ (1) CZ287104B6 (pt)
DE (1) DE69404854T2 (pt)
DK (1) DK0724444T3 (pt)
DZ (1) DZ1817A1 (pt)
ES (1) ES2105774T3 (pt)
FI (1) FI961632A0 (pt)
GR (1) GR3024375T3 (pt)
HR (1) HRP940673B1 (pt)
HU (1) HU227861B1 (pt)
IL (1) IL111293A (pt)
LV (1) LV12103B (pt)
MX (1) MXPA99002296A (pt)
NO (1) NO309927B1 (pt)
NZ (1) NZ275678A (pt)
PL (1) PL184930B1 (pt)
RO (1) RO116864B1 (pt)
SK (1) SK282352B6 (pt)
TW (1) TW382595B (pt)
WO (1) WO1995010284A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547957A (en) * 1993-10-15 1996-08-20 Merck & Co., Inc. Method of treating androgenic alopecia with 5-α reductase inhibitors
NL1005445C2 (nl) * 1997-03-05 1998-09-21 Gho St Holding B V Werkwijze voor het vermenigvuldigen van haar.
US5935968A (en) * 1997-03-17 1999-08-10 Merck & Co., Inc. Methods for treating polycystic ovary syndrome
AU733830B2 (en) 1997-07-29 2001-05-24 Sankyo Company Limited Remedial agent for baldness and other diseases
US6348348B1 (en) 1998-04-07 2002-02-19 The Carnegie Institution Of Washington Human hairless gene and protein
IL124764A0 (en) * 1998-06-04 1999-01-26 Univ Ben Gurion Topical composition for treatment of baldness
JP2002530332A (ja) 1998-11-20 2002-09-17 ザ ゼネラル ホスピタル コーポレーション 毛の成長を促進するためのピレスロイド化合物の使用
WO2001005364A1 (en) * 1999-07-15 2001-01-25 The Procter & Gamble Company Nitrogen-containing steroid compounds and their use to regulate hair growth
ES2158828B1 (es) * 2000-02-22 2002-03-16 Tobajas Maximo Gomez Metodo cosmetico para estimular el nacimiento y el crecimiento del cabello.
DE60027332D1 (de) * 2000-09-04 2006-05-24 Ravi Shrivastava Synergistische pflanzenmischung gegen haarausfall
DK1262177T3 (da) * 2001-05-31 2006-11-20 Pfizer Prod Inc Medicinsk brug af thyromimetiske forbindelser til behandling af hårtab og kompositioner
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
DK1501517T3 (da) 2002-04-24 2007-06-11 Boehringer Ingelheim Pharma Farmaceutisk kombination til behandling af godartet hyperplasia af prostata eller til langtidsforhindring af akut urinretention
FR2954124B1 (fr) * 2009-12-18 2012-04-06 Fabre Pierre Dermo Cosmetique Utilisation du 2,3-dihydroxypropyl dodecanoate pour le traitement de la seborrhee
KR20140003373A (ko) * 2010-08-05 2014-01-09 레가시 헬스케어 홀딩 리미티드 모발 성장 자극 방법
HUE035584T2 (en) * 2011-01-21 2018-05-28 Igisu Co Ltd A therapeutic agent for the treatment of allopathy
GB201102913D0 (en) 2011-02-18 2011-04-06 Univ Birmingham Novel therapeutic
US9345703B2 (en) 2011-09-15 2016-05-24 University Of Kansas Kappa opioid receptor effectors and uses thereof
EP2703003A1 (en) 2012-08-31 2014-03-05 Probelte Biotecnologia S.L. A pomegranate extract and compositions containing pomegranate polyphenols for treating or preventing diseases or physiopathological conditions associated with an excessive gene expression and/or physiological activity of interleukin-6
WO2018229072A1 (de) * 2017-06-16 2018-12-20 Capilli Med Gmbh Zusammensetzung zur verhinderung von haarausfall und wachstumsförderung von haaren
US11331300B2 (en) * 2017-12-22 2022-05-17 Richard Postrel Reversing baldness through follicle regeneration
CN114025768B (zh) 2019-06-28 2023-12-22 古鲁生物制药有限公司 促进毛发生长的药品
FR3106058B1 (fr) * 2020-01-09 2022-01-07 Oreal Procédé de traitement cosmétique
CN113398263B (zh) * 2021-08-06 2022-11-11 广东巧巧生物科技有限公司 一种治疗脱发的洗发水

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
US4396615A (en) * 1981-06-24 1983-08-02 Duke University Method of treating androgen-related disorders
US4885289A (en) * 1983-12-12 1989-12-05 Breuer Miklos M Alteration of character of male beard growth
US5571817A (en) * 1984-02-27 1996-11-05 Merck & Co., Inc. Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
ZA851426B (en) 1984-02-27 1986-10-29 Merck & Co Inc 17 beta-n-monosubstituted carbamoyl-4-aza-5 alpha-androst-1-en-3-ones as 5 alpha reductase inhibitors
IL74365A (en) * 1984-02-27 1990-07-26 Merck & Co Inc 17beta-(n-t.-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one and pharmaceutical compositions containing it
US4684635A (en) * 1984-05-11 1987-08-04 Norman Orentreich Compositions and methods for inhibiting the action of androgens
US5053403A (en) * 1984-05-11 1991-10-01 Norman Orentreich Methods for treatment of male-pattern baldness
DE3888994T2 (de) * 1987-04-03 1994-11-03 Merck & Co Inc Behandlung von androgener Alopecia mit 17-beta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen.
US5228431A (en) * 1990-04-26 1993-07-20 Giarretto Ralph R Drug-free method for treatment of the scalp for therapeutic purposes
DK0542802T3 (da) * 1990-08-10 1996-07-22 Upjohn Co Stimulering af hårvækst med kaliumkanalåbnere og 5alfa-reduktase-inhibitorer
US5175155A (en) * 1991-10-07 1992-12-29 Sterling Winthrop Inc. Win 49596-finasteride method of use and compositions
JPH07508039A (ja) * 1992-05-20 1995-09-07 メルク　エンド　カンパニー　インコーポレーテッド ４−アザステロイドのエステル誘導体
US5795882A (en) * 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
US5407944A (en) * 1993-02-19 1995-04-18 Goldman; Boris E. Compositions and methods for promoting hair growth
US5438061A (en) * 1993-07-16 1995-08-01 Merck & Co., Inc. 7-substituted-δ4-6-azasteroid derivatives as 5α-reductase inhibitors
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
US5547957A (en) * 1993-10-15 1996-08-20 Merck & Co., Inc. Method of treating androgenic alopecia with 5-α reductase inhibitors
US5708001A (en) * 1993-12-17 1998-01-13 Glaxo Wellcome Inc. Substituted 6-azaandrostenones
US5525608A (en) * 1994-04-20 1996-06-11 Merck & Co., Inc. 17b-aryl-4-aza-steroid derivatives useful as 5-alpha-reductase inhibitors
US5512555A (en) * 1994-07-21 1996-04-30 Merck & Co., Inc. Method of treating sweat-related conditions using finasteride, epristeride and a cholestan-3-one
US5595996A (en) * 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
US5777134A (en) * 1995-10-26 1998-07-07 Merck & Co., Inc. 4-oxa and 4-thia steriods
US5756507A (en) * 1995-12-14 1998-05-26 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US5780437A (en) * 1995-12-14 1998-07-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US5849764A (en) * 1995-12-14 1998-12-15 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone

Also Published As

Publication number Publication date
DE69404854T2 (de) 1998-02-19
FI961632A (fi) 1996-04-12
DE69404854D1 (de) 1997-09-11
NO961497L (no) 1996-04-15
HRP940673A2 (en) 1997-02-28
IL111293A (en) 1998-08-16
EP0724444A1 (en) 1996-08-07
CZ287104B6 (en) 2000-09-13
US5824686A (en) 1998-10-20
SK282352B6 (sk) 2002-01-07
GR3024375T3 (en) 1997-11-28
HU227861B1 (en) 2012-05-02
HRP940673B1 (en) 2000-02-29
LV12103A (lv) 1998-08-20
PL316854A1 (en) 1997-02-17
CA2173457C (en) 1999-03-23
NO961497D0 (no) 1996-04-15
BG62756B1 (bg) 2000-07-31
ES2105774T3 (es) 1997-10-16
RO116864B1 (ro) 2001-07-30
CZ108196A3 (en) 1996-08-14
ATE156358T1 (de) 1997-08-15
CN1137237A (zh) 1996-12-04
JP3058351B2 (ja) 2000-07-04
CY2071B1 (en) 1998-09-11
DK0724444T3 (da) 1997-09-15
JPH09505034A (ja) 1997-05-20
IL111293A0 (en) 1994-12-29
EP0724444B1 (en) 1997-08-06
DZ1817A1 (fr) 2002-02-17
NZ275678A (en) 1999-09-29
AU7974294A (en) 1995-05-04
NO309927B1 (no) 2001-04-23
PL184930B1 (pl) 2003-01-31
AU688395B2 (en) 1998-03-12
US5760046A (en) 1998-06-02
WO1995010284A1 (en) 1995-04-20
CA2173457A1 (en) 1995-04-20
US5981543A (en) 1999-11-09
MXPA99002296A (es) 2004-08-27
HU9600976D0 (en) 1996-06-28
HUT74426A (en) 1996-12-30
CN1096861C (zh) 2002-12-25
BR9407824A (pt) 1997-05-06
SK44896A3 (en) 1997-03-05
TW382595B (en) 2000-02-21
LV12103B (en) 1998-10-20
BG100510A (en) 1996-11-29

Similar Documents

Publication Publication Date Title
FI961632A (fi) Menetelmä androgeenisen alopekian hoitamiseksi 5-alfa-reduktaasi-inhibiittoreilla
MY123960A (en) Method of treating androgenic alopecia with 5- alpha reductase inhibitors.
PL312961A1 (en) Amidine derivatives exhibiting activity of nitrogen oxide synthetase
DE69333771D1 (de) Pyran-2-onen und 5,6-dihydropyran-2-onen brauchbar für die Behandlung von Hyperplasie und andere Krankheiten
BR1100217A (pt) Composto, e, composição farmacêutica
AU2838101A (en) Use of melatonin for treating androgenetic and diffuse alopecia
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
CA2157836A1 (en) L-carnitine salt and cosmetic and pharmaceutical compositions containing same for treating dermatoses
DE59913181D1 (de) Zubereitungen zur topischen applikation von antiandrogen wirksamen substanzen
EP0747048A3 (en) Diterpenes and flavonoids as 5-alpha-reductase inhibitors
EP0748221A4 (en) 7-SUBSTITUTED-4-AZA-STEROID DERIVATIVES AS 5-ALPHA REDUCTASE INHIBITORS
GB9110652D0 (en) Composition and method of treating depigmentation disorders
DE69519728D1 (de) 17 beta-aryl-4-aza-steroidderivate
ATE149840T1 (de) Behandlung von leberkrebs
ATE209495T1 (de) Antiatherosclerotische mittel
UA18224A (uk) Спосіб лікуваhhя дерматозів
MX9606553A (es) Estimulo de crecimiento del pelo mediante complejos de peptido-cobre.
UA29236A (uk) Спосіб лікування пізніх гестозів

Legal Events

Date Code Title Description
FC Application refused